Clinical Proteomics Moves Closer to Patient Care

The clinical proteomics market reached an estimated $456 million in 2025 and is expected to grow at a double-digit compound annual growth rate (CAGR) through 2030, according to Kalorama Information’s The Clinical Proteomics Market: Technologies, Applications, and Forecasts to 2030. Yet despite the name, most modern market activity takes place outside routine patient care.

Much of the revenue currently comes from clinical research, pharmaceutical development, biomarker studies, and clinical trials. While technologies capable of measuring hundreds or thousands of proteins are becoming more common, relatively few proteomic tests have entered into everyday clinical practice.

“Clinical proteomics is advancing quickly, but most of the commercial activity still takes place in clinical research, pharmaceutical development, and biomarker studies rather than routine patient testing,” said Justin Saeks, senior analyst and author of Kalorama Information’s report. “The long-term opportunity lies in closing that gap.”

Mass Spectrometry Remains the Foundation

Mass spectrometry (MS) dominates the clinical proteomics market. Modern LC-MS/MS platforms can identify and quantify thousands of proteins and peptides, making them essential for biomarker discovery and translational research.

Leading platforms from Thermo Fisher Scientific, Bruker, and SCIEX continue to improve sensitivity, throughput, and reproducibility. Likewise, suppliers of sample preparation, enrichment, and separation technologies are helping researchers address one of proteomics’ persistent challenges: detecting low-abundance proteins hidden among far more abundant molecules in blood and tissue samples.

As laboratories move from small discovery projects toward larger clinical studies, these supporting technologies have become increasingly important.

Affinity Platforms Expand Proteomics’ Reach

While MS remains central to discovery, affinity-based platforms are becoming an increasingly important part of the market. These technologies use antibodies, aptamers, or other binding molecules to measure predefined sets of proteins, often translating protein signals into nucleic acid readouts that can be analyzed using PCR or next-generation sequencing systems.

That approach provides proteomics direct access to the large installed base of sequencing instruments already in many laboratories.

“The migration of affinity proteomics onto PCR and next-generation sequencing systems is one of the most important changes in the market,” Saeks said. “It allows laboratories to apply familiar genomic infrastructure to protein measurement.”

Rather than replacing mass spectrometry, affinity technologies often complement it. MS remains a powerful discovery tool, while affinity assays are typically used for large-scale testing of selected biomarkers.

Lower Costs Expanding the Market

As happened previously in genomics, declining costs and increasing throughput are expanding the range of studies that can incorporate proteomics.

Large biobank projects are measuring thousands of proteins across massive patient cohorts, linking proteomic, genomic, and clinical data sets. At the same time, vendors are increasingly competing on cost per sample, throughput, workflow simplicity, sensitivity, and scalability rather than on protein coverage alone.

As a result, proteomic profiling is becoming accessible to studies that would have been financially impractical only a few years ago.

Neurology Leads Clinical Adoption

Neurology currently represents the clearest example of proteomics moving into clinical practice.

Blood-based biomarkers such as phosphorylated tau, neurofilament light, GFAP, and amyloid beta are being used to support the evaluation of Alzheimer’s disease and other neurodegenerative disorders. Advances in ultrasensitive detection technologies have made it possible to measure these proteins at extremely low concentrations, creating new opportunities for blood-based testing.

“Neurology has emerged as the clearest early clinical market for proteomics,” Saeks said. “The combination of ultrasensitive blood biomarkers and new Alzheimer’s therapies has created a practical need for tests that can support patient assessment and triage.”

Another major opportunity in oncology. Proteomic technologies are being explored for applications ranging from early cancer detection and treatment selection to monitoring therapy response and minimal residual disease.

The Biggest Challenge Hasn’t Changed

Despite significant advances in technology, the future of clinical proteomics will not be determined solely by the ability to measure more proteins.

Developers must demonstrate that proteomic biomarkers improve clinical decision-making, fit naturally into laboratory workflows, and generate sufficient value to support reimbursement. Many companies are pursuing laboratory-developed tests as an initial commercialization strategy, but adoption still depends on proving clinical utility.

Recent acquisitions across the industry highlight the long-term confidence major life science companies have in protein analysis. Companies including Thermo Fisher Scientific, Illumina, Bruker, Bio-Techne, and Quanterix have been building broader proteomics portfolios that connect instruments, reagents, software, and clinical applications.

For now, clinical research and pharmaceutical development continue to account for most of the market. But as biomarkers become validated and testing moves into routine patient care, clinical diagnostics may ultimately become the industry’s most important growth opportunity.

Find Out More

As proteomics moves from discovery research toward routine patient care, understanding the technologies, companies, and applications shaping the market has never been more important. Explore Kalorama Information’s The Clinical Proteomics Market: Technologies, Applications, and Forecasts to 2030 for comprehensive analysis of this rapidly evolving industry.